The FDA's position on CBD is narrower than most marketing copy admits: CBD cannot be sold as a dietary supplement, cannot be added to conventional food in interstate commerce, and any claim that a product treats or prevents a disease makes it an unapproved drug. Warning letters — many sent jointly with the FTC — follow the disease claims.
Where the FDA actually stands
CBD is an approved prescription drug ingredient. Epidiolex, a seizure medication, contains it, and under federal law an ingredient approved as a drug generally cannot then be sold as a dietary supplement. That is why the FDA holds that CBD supplements and CBD-infused foods are not lawful to market, whatever the label design suggests. In early 2023 the agency went further, saying its existing food and supplement frameworks do not fit CBD and asking Congress to build a new pathway. Until that happens, this is the ground CBD content stands on.
The line that draws warning letters
FDA warning letters to CBD companies are public, posted on the FDA's website, and the pattern in them is unmistakable. The agency quotes marketing copy that names diseases: claims about treating anxiety, curing insomnia, easing arthritis, even fighting cancer or Alzheimer's. Many letters go out jointly with the FTC, which adds its own charge that the claims lack scientific substantiation. The trigger is not selling CBD. It is telling people the product will treat something.
Safer language exists, but it is not a safe harbor
"Supports a sense of calm" reads very differently from "treats anxiety." The first describes intended use in structure-function style; the second names a condition. Distance from disease language does lower risk, but there is a catch specific to CBD. The structure-function claim framework belongs to dietary supplements, and the FDA does not accept CBD as a lawful supplement ingredient, so even soft claims sit on unsettled ground. Treat careful wording as risk reduction, not immunity.
One product paragraph, before and after
Before: "Our 1000 mg tincture treats anxiety and insomnia, reduces chronic pain, and may help prevent cognitive decline." Three named conditions and a prevention claim — four separate problems, each the kind quoted in warning letters.
After: "Our 1000 mg full-spectrum tincture is made from Oregon-grown hemp, extracted with CO2, and batch-tested by an independent lab, with the COA linked on this page. Customers often take it in the evening as part of a wind-down routine." Every sentence is verifiable, and nothing promises a medical outcome.
Google reads this the way regulators do
CBD content lives in YMYL territory, where Google's quality systems expect experience, expertise, and evidence. Pages asserting medical benefits without support tend to struggle in health-adjacent queries, while pages that describe research accurately (what a study measured, in what population, with what result) hold up better with raters and readers alike. Writing to the FDA's line and writing for search quality turn out to be the same discipline.
- The FDA does not accept CBD as a lawful dietary supplement ingredient or food additive.
- Disease claims turn a CBD product into an unapproved drug and drive the warning letters.
- Structure-function wording lowers risk for CBD but is not a formal safe harbor.
- FDA warning letters are public and show exactly which phrases get cited.
- The same claim discipline protects rankings on YMYL queries.
Frequently asked questions
Can CBD be sold as a dietary supplement?
Not under the FDA's current position. CBD was approved as the active ingredient in a prescription drug, and the drug-exclusion rule blocks ingredients approved as drugs from dietary supplement status. Products labeled as CBD supplements are marketed against that position, not with it.
What counts as a disease claim?
Any statement that a product treats, cures, mitigates, or prevents a disease or condition: anxiety, arthritis, insomnia, cancer, and similar names all qualify. Implied claims count too, including testimonials that name conditions and imagery suggesting a medical effect.
Are FDA warning letters public?
Yes. The FDA publishes them on its website, and many CBD letters were issued jointly with the FTC. They are worth reading as a marketer, because they quote the exact sentences that got companies in trouble.
Did the 2018 Farm Bill make CBD marketing legal?
It legalized hemp, defined as cannabis with no more than 0.3 percent delta-9 THC by dry weight, and removed it from the Controlled Substances Act. It explicitly preserved the FDA's authority over food, drugs, and cosmetics, so the claim rules did not move.
Is a phrase like supports relaxation acceptable?
It is far lower risk than disease language and widely used, but the FDA has not blessed structure-function claims for CBD because it does not treat CBD as a lawful supplement. Keep wording soft, skip condition names, and be able to support anything objective you say.
General information for cannabis marketers, not legal advice.
Want this done for your brand?
We build cannabis & CBD search visibility with full transparency, for dispensaries, brands, and MSOs.
Get a free cannabis SEO audit ›